Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Greenwich LifeSciences, Inc.
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
27 mars 2025 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
17 mars 2025 06h45 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
10 févr. 2025 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
29 janv. 2025 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
27 janv. 2025 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
23 janv. 2025 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Provides Update on Commercial Manufacturing
22 janv. 2025 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01
14 janv. 2025 06h15 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France
13 janv. 2025 07h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Partners with GIM in Italy
26 nov. 2024 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...